R. Lee

发表

Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM).

K. Flaherty, J. Sosman, A. Ribas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy Endpoints of RTOG 0247: A Randomized Phase II Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients with Locally Advanced Rectal Cancer

B. Erickson, A. Rashid, C. Willett, 2015 .

Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT).

M. Ratain, K. Flaherty, M. Gore, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma.

K. Flaherty, D. Tuveson, B. Weber, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study.

A. Einstein, T. Fleming, C. Tangen, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma.

Ruey-min Lee, T. Bekaii-Saab, A. Deal, 2016, Journal of Clinical Oncology.

A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (Trial ****)

M. Michaelson, H. Sandler, G. Swanson, 2017 .

Combination Therapy With Ixabepilone Plus Capecitabine Is Effective in ER/PR/HER2-Negative Breast Cancer Resistant to Anthracyclines and Taxanes

M. Piontek, H. Roché, M. Verrill, 2008 .

Efficacy of vemurafenib (V), a selective V600Eb-raf inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.

D. Heimbrook, B. Higgins, K. Kolinsky, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

J. Blay, G. Demetri, A. Cesne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma.

A. Oza, F. Haluska, S. Pignata, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.

S. Chandarlapaty, C. Swanton, Y. Janjigian, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas.

M. Camborde, J. Hamm, R. Ma, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Stereotactic Body Radiotherapy for Large Unresectable Hepatocellular Carcinomas - A Single Institution Phase II Study.

C. Mar, E. Yoshida, R. Ma, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer.

K. Flaherty, J. Sosman, R. J. Lee, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of Locoregional Control in Head and Neck Squamous Cell Carcinoma with Serial CT Perfusion during Radiotherapy

A. Ozonoff, M. Truong, O. Sakai, 2011, American Journal of Neuroradiology.

Penile cancer: current therapy and future directions.

G. Sonpavde, R. J. Lee, T. Dorff, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma.

F. Cabanillas, E. Freireich, R. Lee, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

P. Kantoff, M. Michaelson, R. J. Lee, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

P. Kantoff, M. Michaelson, J. Bellmunt, 2012 .

Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts).

K. Flaherty, J. Sosman, A. Ribas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

D. Grignon, K. Bae, J. Speight, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.

A. Hauschild, K. Flaherty, P. Ascierto, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.